Related Experiment Video

Updated: Jul 23, 2026

A Novel Clinical Grade Isolation Method for Human Kidney Perivascular Stromal Cells
09:05

A Novel Clinical Grade Isolation Method for Human Kidney Perivascular Stromal Cells

Published on: August 7, 2017

Lessons learned from the use of COVID-19 convalescent plasma at Kaiser Permanente

Kevin Tse1, Qiaoling Chen2, Ariadna Padilla2

  • 1Department of Allergy and Immunology, Southern California Permanente Medical Group, San Diego Kaiser Permanente Medical Center, San Diego, Calif.

The Journal of Allergy and Clinical Immunology. Global
|September 2, 2022
PubMed

Insights

COVID-19 convalescent plasma (CCP) did not significantly reduce mortality in a large-scale study. Recommendations for future use include antibody testing and early administration.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Critical Care Medicine

Background:

  • Contradictory findings exist regarding the efficacy of COVID-19 convalescent plasma (CCP).
  • Some studies suggest CCP reduces mortality, while others show no benefit.

Purpose of the Study:

  • To analyze CCP implementation and efficacy in a large healthcare system.
  • To reconcile conflicting data on CCP's effectiveness.
  • To provide guidance on future convalescent plasma use.

Main Methods:

  • Retrospective analysis of 2,831 CCP-treated COVID-19 patients vs. 18,475 controls.
  • Multivariable analysis controlling for clinical and demographic factors.
  • Retrospective testing of CCP units for SARS-CoV-2 antibodies.

Main Results:

  • CCP transfusion did not significantly impact 30-day or 5-month mortality rates.
  • Odds ratio for mortality: 1.04 (95% CI, 0.87-1.25).
  • Hazard ratio for mortality: 1.05 (95% CI, 0.93-1.19).

Conclusions:

  • CCP showed no significant benefit in reducing mortality in this large cohort.
  • Future use recommendations include patient antibody status, early administration, and antibody level quantification.
  • Consider fractionated hyperimmune globulin as an alternative therapy.
Abstract

Keywords:
COVID-19convalescent plasma

More Related Videos

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells07:37

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

Published on: November 17, 2017

COVID-19 Seroprevalence Test for IgG Antibody Levels Among Healthy Donors Across Different Pandemic Phases in Jeddah04:43

COVID-19 Seroprevalence Test for IgG Antibody Levels Among Healthy Donors Across Different Pandemic Phases in Jeddah

Published on: June 24, 2025

Related Concept Videos

Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...